Introduction
Vaccination represents one of the major successes of medicine as it has spared countless people from polio, tetanus and other acute infections 1 . At present, no less than 26 infectious diseases can be prevented through vaccination 2 . With a notable exception of smallpox [3] [4] [5] and yellow fever 6 vaccines which generate cellular immunity, classical preventive vaccines are designed to generate neutralizing antibodies. Yet, some viruses that cause considerable morbidity and mortality in humans escape the immune control elicited by these vaccines 7, 8 . For example, no universally effective vaccines have yet been developed for respiratory syncytial virus (RSV), hepatitis C virus and human immunodeficiency virus (HIV) 8, 9 . Among possible causes for the escape from neutralizing antibodies are genetic diversity and mutational evolution of these viruses. Therefore, novel strategies for protective vaccination against these viruses need to take into consideration other immune effectors, i.e., CD8 + T cells 10 . Indeed, CD8 + T cell-mediated protective responses might prove beneficial by, e.g., elimination of infected cells which will limit viral replication and, consequently, disease development 11 . CD8 + T cells also appear as important players in therapeutic vaccination in conditions such as chronic infections and
cancer.
An essential component of vaccination are dendritic cells (DCs), antigenpresenting cells (APCs) of skin and mucosal surfaces that capture vaccine antigens and present them to lymphocytes 12 . DCs constitute a system of professional APCs, which initiate, maintain and regulate adaptive immune
For personal use only. on . by guest www.bloodjournal.org From 4 responses 13 . Recent studies corroborate a concept of distinct DC subsets generating quantitatively and qualitatively distinct types of adaptive immunity 14, 15 .
This is fundamental for the rational design of new, improved, vaccines. However, studies of human DC biology are mostly confined to in vitro systems and are hampered by the lack of in vivo models. These shortcomings cannot be fully addressed by murine studies because mice and humans differ in several aspects of DC biology, an example of this being the pattern of toll-like receptor (TLR) 9
expression which is present on all DCs in the mouse but only on plasmacytoid DCs (pDCs) in the human 16 . Thus, mice would not accurately predict how certain TLR ligands would impact vaccine immunogenicity in humans. These differences in DC biology might also explain considerable discrepancies between mouse and human in the outcomes of DNA vaccination 17 . Thus, while highly effective in mouse models, DNA vaccines are clearly less immunogenic in humans 18 .
To test human vaccines in vivo, we embarked upon the construction of mice with human immune system following the pioneering studies of the late 80's [19] [20] [21] . 
Materials and Methods

Antibodies and Reagents
Antibodies to human CD3 (SK7), CD4 (SK3), CD8 (SK1), CD11c (S-HCL-3), 
Analysis
Mice were euthanized and blood was collected with heparin. After flushing out blood, the lungs were harvested for single cell suspension. The lungs were digested with 2 mg/mL of collagenase D (Roche Diagnostics, Indianapolis, IN) for 30 minutes at 37°C. Single cell suspension was made with two frosted slides and the debris was removed by filtering through a 70 μm cell strainer (BD).
Spleen was digested for 10 minutes using the same method. Single cell suspensions were further purified for ex vivo analysis.
Phenotype analysis
Cells were first treated with purified antibody against murine CD16/32 (2.4G2, BD; to block nonspecific FcR interactions) and then stained on ice with FITC, phycoerythrin (PE), peridinin chlorophyll protein (PerCP), and allophycocyanin (APC) conjugated specific antibodies, or appropriate isotype controls. After washing twice with PBS, cells were fixed with FACSlysis solution (BD) or 1% paraformaldehyde and analyzed for up to six parameters on a FACSCalibur (BD) using CellQuest software (BD) or FlowJo software (Tree Star, Ashland, OR).
Tetramer Analysis
Heparinized blood or single cell suspension from different tissues were resuspended in PBS-2% FCS. Each sample was stained with FITC, PE, PerCP or APC conjugated antibody to CD8 and CD3 for surface marker and PE or APC 
Intracellular Cytokine staining
Intracellular cytokine and degranulation of CD8 + T cells were examined using a modified protocol as described 28 . Briefly, total cell suspension from vaccinated mice was stimulated with 2.5 μg/mL of specific peptide in the presence of anti- Table S2 ). Altogether 9/14 mice showed expansion of FluM1-specific CD8 + T cells in the blood (mean = 0.26% ± SEM = 0.07%, n=14 mice, p=0.005; Fig. 1c and cells (mean = 0.03% ± SEM = 0.007%, n=7; Fig. 1c and Table S2 ). Thus, the expansion of FluM1-specific CD8 + T cells in LAIV vaccinated mice is driven by the presentation of influenza antigen indicating specificity. (Fig. 2a) . Such results were reproduced in five independent cohorts of humanized mice generated using cells from four different HLA-A*0201 healthy volunteers ( Fig. 2b and Table S3 ).
Altogether 15/17 mice vaccinated with TIV showed expansion of FluM1-specific CD8 + T cells (mean = 0.50% ± SEM = 0.12, n=17; Fig. 2b and Table S3 ). FluM1-specific CD8 + T cells binding tetramers with high intensity could also be detected in the spleen and lungs (Fig. 2c) . These results suggest that antigens of the Fig. 3a and b) . Both cohorts were reconstituted with the same number of T cells (20 x 10 6 per mouse). As shown in Fig. 3c , these partially reconstituted mice did not expand FluM1-specific CD8 + T cells in response to TIV vaccine while the 3/3 control humanized mice did (Fig.   3d ). FluM1-specific CD8 + T cells could not be detected at day 27 ( Fig. 3e) , indicating a complete absence of response rather than a delayed response. The lack of FluM1-specifc CD8 + T cell response in the blood of partially reconstituted mice was not related to the absence of CD8 + T cells which could be detected at all time points and increased with time (Fig. 3f) . Furthermore, even after a boost vaccination at day 27, spleens of NOD/SCID β2m -/-mice that were transferred with T and B cells did not harbor FluM1-specific CD8 + T cells (Fig. S2) . The kinetics analysis in fully reconstituted humanized mice showed a peak response in blood at day 12 followed by a gradual disappearance of influenza antigenspecific CD8 + T cells by day 20. The disappearance of FluM1-specific CD8 + T cells in fully reconstituted mice was not related to the disappearance of human CD8 + T cells (Fig. 3f) (Fig. 4a) . This analysis showed responses to FluM1 (0.8% CD8 + T cells in the spleen, Fig. 4a ) thus confirming the tetramer binding data (Fig. 1 ). NS1-specific CD8 + T cell expansion could also be detected These findings were reproduced in two independent cohorts of mice For personal use only. on . by guest www.bloodjournal.org From reconstituted with cells from two different healthy volunteers (Fig. 4d) . The lack of NS1-specifc CD8 + T cell differentiation was further confirmed by the lack of CD8 + T cells binding NS1 peptide-loaded tetramer in the blood of mice vaccinated with TIV (Fig. 4e) .
Trivalent influenza vaccines expand CD8 + T cells with different effector phenotypes
To further establish differentiation of antigen-specific CD8 + T cells into effector Fig. 5a ).
Analysis of draining lymph nodes (pooled cervical and mediastinal lymph nodes)
revealed the presence of FluM1-specific CD8 + T cells (Fig. 5b) . CD8 + T cells with For personal use only. on . by guest www.bloodjournal.org From
